Speaker Manuscripts

s of the International Society for Influenza and other Respiratory Virus Diseases. Hong Kong SAR, China: Options for the Control of InfluenAntiviral susceptibility of pandemic influenza in a selfsampling, oseltamivir treated community surveillance scheme in the UK za VII, 2010:154. 41 Lackenby A, Miah S, Medina M-J et al. A study to assess emergence and transmissibility of neuraminidase inhibitor resistance following treatment of children and adults with acute pandemic influenza [abstract P-185]; in Program and abstracts of the International Society for Influenza and other Respiratory Virus Diseases. Hong Kong SAR, China: Options for the Control of Influenza VII, 2010:154. 42 Meijer A, Boucher C, van den Broek PJ et al. Clinical findings, viral loads, response to therapy, and resistance monitoring in the first 126 patients with pandemic A (H1N1) 2009 influneza in the netherlands [abstract O-827]. in Program and abstracts of the International Society for Influenza and other Respiratory Virus Diseases Hong Kong SAR, China: Options for the Control of Influneza VII. 2010:24. 43 Schutten M, Boucher C, Lina B et al. Neuraminidase inhibitor (NAI) Treatment in a 2009-H1N1 influenza A-infected patient population: The IRIS study [abstract P-167]; in Program and abstracts of the International Society for Influenza and other Respiratory Virus Diseases. Hong Kong SAR, China: Options for the Control of Influenza VII, 2010:144. 44 Stephenson I, Democratis J, Lackenby A et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009; 48:389–396. 45 Harvala H, Gunson R, Simmonds P et al. The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, NovemberDecember, 2009. Euro Surveill 2010; 15:pii-19536. 46 Memoli MJ, Hrabal RJ, Hassantoufighi A et al. Rapid selection of oseltamivirand peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252–1255. 47 Moore C, Galiano M, Lackenby A et al. Evidence of person to person transmission of oseltamivir resistant pandemic influenza A (H1N1) 2009 virus in a hematology unit. J Infect Dis 2010; 203:18– 24. 48 Tramontana AR, George B, Hurt AC et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16:1068– 1075. 49 Valinotto LE, Diez RA, Barrero PR et al. Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus. Antivir Ther 2010; 15:923–927. 50 Wolfe C, Greenwald I, Chen L. Pandemic (H1N1) 2009 and oseltamivir resistance in hematology ⁄ oncology patients. Emerg Infect Dis 2010;16:1809–1811. 51 Duan S, Boltz DA, Seiler P et al. Oseltamivir-resistant pandemic H1N1 ⁄ 2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010; 6:e1001022. 52 Hamelin ME, Baz M, Abed Y et al. Oseltamivir-resistant pandemic A ⁄ H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 2010; 6:e1001015. 53 Kiso M, Shinya K, Shomojima M et al. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. Plos Pathog 2010; 6:e1001079. 54 Seibert CW, Kaminski M, Philipp J et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 2010; 84:11219–11226. 55 Cheng PK, To AP, Leung TW et al. Oseltamivirand amantadineresistant influenza virus A (H1N1). Emerg Infect Dis 2010; 16:155– 156. 56 Le QM, Wertheim HF, Tran ND et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010; 362:86–87. 57 World Health Organization update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec 2009; 85:37–40. 58 Garrison M, Weldon L, Brantley P et al. Oseltamivri-resistant 2009 pandemic influenza A (H1N1) vius infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR 2009; 58(No.35): 969–992. CDC. 59 Pizzorno A, Bouhy X, Abed Y et al. Generation and characterization of recombinant pandemic influenza A ⁄ H1N1 viruses resistant to neurmindase inhibitors. J Infect Dis 2010; 203:25–31. 60 Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009; 53:4433–4440. 61 Rousset D, Goff J, Abou-Jaoude G et al. Emergence of successive mutations in the neuraminidase of the pandemic H1N1 virus respectively associated with oseltamivri resistance and reduced susceptibility to both oseltamivir and zanamivir under treatment with neuraminidase inhibitors [abstract P-198]; in Program and abstracts of the International Society for Influenza and other Respiratory Virus Diseases. Hong Kong SAR, China: Options for the Control of Influenza VII, 2010:162. 62 Takashita E, Ujike M, Ejima M et al. Detection and characterizations of oseltamivir-resistant pandemic influenza A ⁄ H1N1 2009 viruses in the 2009 ⁄ 10 season in Japan [abstract P-175]; in Program and abstracts of the International Society for Influenza and other Respi-s of the International Society for Influenza and other Respiratory Virus Diseases. Hong Kong SAR, China: Options for the Control of Influenza VII, 2010:149. 63 van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrugresistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:1381–1382. 64 Nguyen H, Fry A, Loveless PA et al. Recovery of a MultidrugResistant Strain of Pandemic Influenza A 2009 (H1N1) Virus a 2011 Blackwell Publishing Ltd, Influenza and Other Respiratory Viruses, 5 (Suppl. 1), 2–53 25 Options for the control of influenza VII